Findings
========

Background
----------

In 1971, the first human pathogenic polyomaviruses (PyV) BKV and JCV were discovered in severely immunosuppressed patients \[[@B1],[@B2]\]. Since then, BKV and JCV have been detected in various sample types from different organ systems including urine specimens, serum samples and leukocytes, which seem to form the vehicle for virus spread \[[@B3]-[@B6]\].

The two polyomaviruses WU polyomavirus (WUPyV) and KI polyomavirus (KIPyV) were first described in 2007 \[[@B7],[@B8]\]. Recent findings imply that primary contact occurs during childhood resulting in a persistent infection \[[@B9]-[@B11]\]. They have mainly been detected in respiratory tract (RT) secretions (RTS) but also in stool samples \[[@B7],[@B12]-[@B17]\], raising the question of a causal connection to gastrointestinal (GI) symptoms \[[@B13]-[@B16],[@B18]\]. So far, however, no clear association between virus detection and specific symptoms could be shown. Like previously described for BKV/JCV, an association between the appearance of WUPyV/KIPyV and immunosuppression -- especially with hematopoietic stem cell transplantation (HSCT) - has repeatedly been observed \[[@B9],[@B13],[@B14],[@B19]\]. In analogy to findings of BKV and JCV in leukocytes \[[@B3]-[@B6]\], a hematologic reservoir is also suspected for WUPyV and KIPyV \[[@B16]\].

To elucidate the tissue tropism of these viruses many studies followed a cross-sectional design. Such studies, however, have not revealed significantly different prevalence rates for patients and control groups \[[@B20],[@B21]\]. Hence, as seen for BKV/JCV, quantitative assignment of viral loads could be indicative for clinically relevant viral replication \[[@B22]\]. This theory is supported by a recent study reporting higher KIPyV loads in RTS of patients undergoing HSCT than of the control group \[[@B20]\].

As mentioned, WUPyV/KIPyV DNA has been detected in stool samples. However, a common challenge when detecting viral DNA in the GI tract is the differentiation between possibly pathogenic primary replication and secondary shedding due to swallowed virus \[[@B23]\]. This problem can only be addressed by longitudinal viral DNA quantification in different simultaneously collected sample types.

Therefore, we performed this retrospective analysis to provide quantitative viral load data in different specimens of patients undergoing HSCT. Furthermore, we address the question of genuine viral replication in the gastrointestinal tract as opposed to detection of viral DNA by polymerase chain reaction (PCR) due to secondary shedding from the respiratory system.

Material and methods
--------------------

A retrospective analysis for the prevalence of WUPyV and KIPyV in HSCT-patients was performed with a total of 449 clinical samples from 37 HSCT-patients. These patients were routinely screened for viral pathogens throughout HSCT-therapy, which comprised WUPyV and KIPyV as well as EBV, CMV, HHV6 and Adenovirus. In case of a clinical suspicion, further PCR testing was performed for HSV, Norovirus, Rotavirus, Parvovirus B19, Influenza virus and Parainfluenza virus.

The study was conducted in accordance with the Declaration of Helsinki. All patients gave informed consent to virological surveillance, collection and publication of data. Approval was waived by the ethics committee of the Ludwig-Maximilians-University.

Assays were carried out according to standard detection techniques of the accredited laboratory for virological diagnostics of the Max von Pettenkofer-Institute.

The study comprised RTS (throat washes, bronchoaleveolar lavages, endotracheal suctions), stool and urine samples and leukocytes. Samples were stored at 4°C and nucleic acid was extracted within 24 h with the High Pure Viral Nucleic Acid Kit (Roche Applied Biosystems). Leukocytes were adjusted to a cell number of 20,000 cells/assay. Quantitative real time-PCR was performed as previously described \[[@B24]\] as an *in house* test with slightly modified primers: 5'-TTGGATGAAAATGGCATTGG-3', 5'-AACCCTTCTTTGTCTAAARTGTAGCC-3'; Probes: WU: 5'-FAM-CATAACTTGTGCTGACCTTTTGGGAGTTAAC-BHQ1-3', KI: 5'-HEX-ACATTACTTGTGCAGATATGCTTGGAACAGC-BHQ1-'3 (ELLA Biotech GmbH, Martinsried, Germany). Positive control plasmids for WUPyV and KIPyV were kindly provided by Benedikt Weißbrich (University of Würzburg, Germany).

The sensitivity threshold of the assay with a detection probability of 90% was 7 copies/20,000 cells for leukocytes and was 350 copies/ml for RTS, stool and urine samples, corresponding to 2.54 log copies/ml.

RTS and stool samples that tested positive were matched to define the mean difference between viral loads in RTS and stool samples.

Our statistical inference regarding the differences in log viral loads was based on a two-sided paired t test. A p value \< 0.05 was regarded as significant.

Results
-------

### Initial analysis

During the initial analysis, 19 out of 208 specimens taken from 37 patients tested positive for WUPyV or KIPyV. Positive results could be assigned to 5 patients (total number of samples from these 5 patients: 64) (Table[1](#T1){ref-type="table"}). KIPyV was detectable in RTS and stool samples from 4 adult patients, whereas WUPyV was found in RTS, stool and urine samples of an infant.

###### 

Characteristics of the 5 hematopoietic stem cell transplantation (HSCT) patients presenting WUPyV or KIPyV

  **Virus**                     **Patient**          **Transplant type**                                       **GvHD**                                                  **Antiviral therapy**                      **Co-infecting viruses in RTS**   **Co-infecting viruses in stool**   **Co-infecting viruses in further samples**
  ---------------------------- ------------- ------------------------------------ ------------------------------------------------------------------ ------------------------------------------------------------- --------------------------------- ----------------------------------- ---------------------------------------------
  **KIPyV (adult patients)**         1        Double Cord-Blood- Transplantation                    Chronic (skin, gut - max. IV°)                                   Cidofovir (days +121 to +272)                             HHV6, HSV                            HHV6                     HHV6 (leukocytes), BKV, HHV6 (urine)
                                     2                 Allogeneic PBSCT                            Chronic ( skin, gut - max. IV°)                             Cidofovir, Ribavirin ( days +118 to +176)                    EBV, HHV6, HSV                     Adenovirus, EBV                EBV, HHV6, Adenovirus (leukocytes)
                                     3                  Allogeneic BMT                                 Acute (skin - max. II°)                        Foscarnet ( days +19 to +55), Cidofovir ( days +55 to +138)              HHV6, EBV                            none                               EBV (leukocytes)
                                     4                 Allogeneic PBSCT                                Acute (gut - max. III°)                                                   none                                            HHV6                               HHV6                            HHV6, EBV (leukocytes)
  **WUPyV (infant)**                 5                 Allogeneic PBSCT            Chronic (pre-PBSCT: skin, gut, hematopoietic system - max. III°)                  Cidofovir ( days +17 to +58)                     HHV6, Adenovirus, HHV7, HSV        Norovirus, Adenovirus, HHV6                     HHV6 (urine)

Clinical data summary for the HSCT patients that tested positive for WUPyV and KIPyV including detected co-infecting viruses throughout the observation period and antiviral therapy; Antiviral therapy: all patients received prophylactic Acyclovir therapy. Further antiviral therapy is depicted with time-points (day 0: day of HSCT). Co-infecting viruses in RTS, stool and further samples in order of detection frequency. GvHD: Graft versus Host Disease; RTS: respiratory tract samples, PBSCT: peripheral blood stem cell transplantation.

### Follow-Up

In these 5 patients, viral loads were defined over time in another 241 samples from different organ sites (RTS, stool, leukocytes, urine; total: 305 samples) (Figure [1](#F1){ref-type="fig"}[2](#F2){ref-type="fig"}). All patients had a period of diarrhea during HSCT which coincided with detection of WUPyV/KIPyV, but also with mucositis and Graft versus Host Disease (GvHD -- stages were defined according to Glucksberg et al. \[[@B25]\]) of the gut and detection of co-infecting pathogenic viruses (Table[1](#T1){ref-type="table"}). Thus, primary and possibly pathogenic replication in the gastrointestinal tract needed to be differentiated from secondary shedding events from the RT. For this purpose, RTS and stool specimens collected with a maximum time difference of 24 hours were matched in pairs (n = 34) and viral load differences were defined. A significant mean viral load difference of 2.3 log copies/ml was determined between these 2 sample types (p \< 0.001).

![**Courses of KIPyV load in respiratory tract samples and stool samples in 4 adult patients.** Quantitative Real Time-PCR was performed to determine viral loads (copies/ml) in different specimens before and after hematopoietic stem cell transplantation (HSCT). The 90% sensitivity threshold was at 350 copies/ml corresponding to 2.54 log copies/ml indicated by the horizontal dotted line. The bold line represents day 0 of HSCT; the dashed vertical line shows time point of neutrophil granulocyte engraftment. Please note that most samples were collected after HSCT. RTS: respiratory tract secretion.](1743-422X-9-209-1){#F1}

![**Courses of WUPyV viral load in respiratory tract samples, stool and urine samples in infant patient 5.** Quantitative Real Time-PCR was performed to determine viral loads (copies/ml) in different specimens before and after hematopoietic stem cell transplantation (HSCT). The 90% sensitivity threshold was at 350 copies/ml corresponding to 2.54 log copies/ml indicated by the horizontal dotted line. The bold line represents day 0 of HSCT; the dashed vertical line shows time point of neutrophil granulocyte engraftment. RTS: respiratory tract secretion.](1743-422X-9-209-2){#F2}

Repeated testing of leukocytes showed neither KIPyV nor WUPyV. Leukocyte-associated viremia was therefore not seen in these patients despite simultaneous detection of high viral titers in other specimens and the severe immunosuppression throughout HSCT-therapy.

A pediatric patient presented WUPyV in feces and RTS as well as in urine samples (Figure[2](#F2){ref-type="fig"}). Previous studies indicate that primary infection with WUPyV/KIPyV occurs during childhood \[[@B9]-[@B11]\]. Thus, this could have been a case of primary infection for WUPyV which led to virus detection in the urine with lower viral loads than in RTS and stool samples.

KIPyV was not detectable in urine samples at any time point.

Prophylactic therapy with Acyclovir was routinely performed for all patients under HSCT. Further antiviral therapy is depicted in Table[1](#T1){ref-type="table"}. All patients presented HHV6, among other co-infecting viruses (Table[1](#T1){ref-type="table"}).

Patients 1 and 2 had chronic Graft versus Host Disease (maximum WHO stage 4) until the end of the observation period that was treated with high doses of various immunosuppressants including Infliximab. Patient 1 developed a BKV-associated hemorrhagic cystitis. For this reason and for the HHV6-infection (Table[1](#T1){ref-type="table"}), antiviral therapy with Cidofovir was initiated on day +121 and lasted till the end of observation. While he could not clear BKV throughout the course of analysis, he did clear KIPyV (Figure[1](#F1){ref-type="fig"}).

Patient 2 was treated with Cidofovir and Ribavirin from day +118 to +176. From day +71 to +99 he had received 5 doses of Infliximab. The first time-point of virus detection was at day +82, followed by a steady decline and clearing of KIPyV until day + 246 (Figure[1](#F1){ref-type="fig"}).

Patient 3 was treated with Foscarnet and Cidofovir for HHV6 and EBV (Table[1](#T1){ref-type="table"}) from day +55 to +138. Clearing of virus coincided with antiviral treatment and neutrophil engraftment.

Patient 4 did not receive further antiviral therapy and cleared the virus after a viral load peak of 6.1 log copies/ml 21 days after neutrophil engraftment.

Patient 5 presented WUPyV among various co-infecting viruses. For an adenoviral infection, he was treated with Cidofovir from day +17 to +58, which coincides with clearing of the virus from the urine, but not in RTS or stool samples.

Conclusions
-----------

In this retrospective longitudinal study, a total of 449 samples (RTS, stool, urine, leukocytes) from 37 HSCT-patients were quantitatively analyzed for the polyomaviruses WUPyV and KIPyV. KIPyV was found in RTS and stool samples of four adult patients, while an infant presented WUPyV in RTS and stool samples as well as in urine.

Recent studies raised the question of a causal connection between WUPyV/KIPyV detection in the stool and the appearance of GI symptoms \[[@B13]-[@B16],[@B18]\]. In this study, viral loads in RTS and stool samples correlated consistently. A mean viral load difference of 2.3 log copies/ml (p \< 0.001) between respiratory and stool samples was observed. This suggests the RT as the primary site of replication with virus detection in feces resulting from swallowed virus. We conclude that, when screening for WUPyV or KIPyV in stool samples to define associated symptoms, respiratory secretions should be simultaneously analyzed to rule out viral shedding from the respiratory tract.

These polyomaviruses were repeatedly detected in all 5 patients and viral load courses could be quantified. Clearing of KIPyV coincided with Cidofovir therapy in patients with severe immunosuppressive therapy due to high-grade GvHD and with immune reconstitution as determined by neutrophil granulocyte engraftment in patients with moderate immunosuppressive therapy, respectively. Cidofovir is a treatment option for BKV \[[@B4]\], and might therefore have antiviral activity on related viruses, such as WUPyV or KIPyV. Therefore, more studies are needed to exclude or to specify a possible impact of this substance and to further define factors associated with viral replication taking into account clinical symptoms as well as medication and immune status.
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